Abstract
Purpose
To develop a predictive model for circuit clotting in patients with continuous renal replacement therapy (CRRT).
Methods
A total of 425 cases were selected. 302 cases were used to develop a predictive model of extracorporeal circuit life span during CRRT without citrate anticoagulation in 24 h, and 123 cases were used to validate the model. The prediction formula was developed using multivariate Cox proportional-hazards regression analysis, from which a risk score was assigned.
Results
The mean survival time of the circuit was 15.0 ± 1.3 h, and the rate of circuit clotting was 66.6 % during 24 h of CRRT. Five significant variables were assigned a predicting score according to the regression coefficient: insufficient blood flow, no anticoagulation, hematocrit ≥0.37, lactic acid of arterial blood gas analysis ≤3 mmol/L and APTT < 44.2 s. The Hosmer–Lemeshow test showed no significant difference between the predicted and actual circuit clotting (R 2 = 0.232; P = 0.301).
Conclusions
A risk score that includes the five above-mentioned variables can be used to predict the likelihood of extracorporeal circuit clotting in patients undergoing CRRT.
Similar content being viewed by others
References
Ronco C, Bellomo R, Ricci Z (2001) Continuous renal replacement therapy in critically ill patients. Nephourol Dial Transplant 16(Suppl 5):67–72
Uchino S, Bellomo R, Morimatsu H et al (2007) Continuous renal replacement therapy: a worldwide practice survey. Intensive Care Med 33:1563–1570
Vanholder R, Van Biesen W, Lameire N (2001) What is the renal replacement method of first choice for intensive care patients? J Am Soc Nephourol 12(suppl 17):S40–S43
Kleger G, Fassler E (2010) Can circuit lifetime be a quality indicator in continuous renal replacement therapy in the critically ill? Int J Artif Organs 33:139–146
Wald R, Friedrich JO, Bagshaw SM et al (2012) Optimal Mode of clearance in critically ill patients with Acute Kidney Injury (OMAKI)-a pilot randomized controlled trial of hemofiltration versus hemodialysis: a Canadian Critical Care Trials Group project. Crit Care 16:R205
Kim B, Fealy N, Baldwin I, Bellomo R (2011) Insertion side, body position and circuit life during continuous renal replacement therapy with femoral vein access. Blood Purif 31:42–46
Joannidis M, Oudemans-van Straaten HM (2007) Clinical review: patency of the circuit in continuous renal replacement therapy. Crit Care 11:218
Cutts MW, Thomas AN, Kishen R (2000) Transfusion requirements during continuous veno-venous haemofiltration: the importance of filter life. Intensive Care Med 26:1694–1697
Webb AR, Mythen MG, Jacobsen D, Mackie IJ (1995) Maintaining blood flow in the extracorporeal circuit: hemostasis and anticoagulation. Intensive Care Med 21:84–93
Hackbarth R, Bunchman TE, Chua AN (2007) The effect of vascular access location and size on circuit survival in pediatric continuous renal replacement therapy: a report from the PPCRRT registry. Int J Artif Organs 30:1116–1121
Baldwin I, Bellomo R, Koch B (2004) Blood flow reductions during continuous renal replacement therapy and circuit life. Intensive Care Med 30:2074–2079
Holt A, Bierer P, Bersten A, Bury L, Vedig A (1996) Continuous renal replacement therapy in critically ill patients: monitoring circuit function. Anaesth Intensive Care 24:423–429
Padrini R, Canova C, Conz P, Mancini E, Rizzioli E, Santoro A (2005) Convective and adsorptive removal of β2-microglobulin during predilutional and postdilutional hemofiltration. Kidney Int 68:2331–2337
Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R (2003) Pre-dilution vs. post-dilution during continuous veno-venous hemofiltration: impact on filter life and azotemic control. Nephron Clin Pract 94:c94–c99
Unger JK, Haltern C, Portz B, Dohmen B, Gressner A, Rossaint R (2001) Relation of haemofilter type to venous catheter resistance is crucial for filtration performance and haemocompatibility in CVVH–—an in vitro study. Nephourol Dial Transplantat 21:2191–2201
Zhu LP, Zhang XX, Xu L, Du CH, Zhu BK, Xu YY (2007) Improved protein-adsorption resistance of polyethersulfone membranes via surface segregation of ultrahigh molecular weight poly(styrene-alt-maleic anhydride). Coll Surf B Biointerfaces 57:189–197
Melly MA, Meng HC, Schaffner W (1975) Microbiol growth in lipid emulsions used in parenteral nutrition. Arch Surg 110:1479–1481
Mershon J, Nogami W, Williams JM, Yoder C, Eitzen HE, Lemons JA (1986) Bacterial/fungal growth in a combined parenteral nutrition solution. JPEN J Parenter Enter Nutr 10:498–502
Gilbert M, Gallagher SC, Eads M, Elmore MF (1986) Microbial growth patterns in a total parenteral nutrition formulation containing lipid emulsion. JPEN J Parenter Enter Nutr 10:494–497
Maki DG, Martin WT (1975) Nationwide epidemic of septicemia caused by contaminated infusion products. IV. Growth of microbial pathogens in fluids for intravenous infusions. J Infect Dis 131:267–272
Del Castillo J, Lopez-Herce J, Cidoncha E et al (2008) Circuit life span in critically ill children on continuous renal replacement treatment: a prospective observational evaluation study. Crit Care 12:R93
Su HM, Lin TH, Hsu PC et al (2013) Global left ventricular longitudinal systolic strain as a major predictor of cardiovascular events in patients with atrial fibrillation. Heart 99:1588–1596
Palomba H, de Castro I, Neto AL, Lage S, Yu L (2007) Acute kidney injury prediction following elective cardiac surgery: AKICS Score. Kidney Int 72:624–631
Rassi A Jr, Rassi A, Little WC et al (2006) Development and validation of a risk score for predicting death in Chagas’ heart disease. N Engl J Med 355:799–808
Sullivan LM, Massaro JM, D’Agostino RB Sr (2004) Presentation of multivariate data for clinical use: the Framingham study risk score functions. Stat Med 23:1631–1660
Uchino S, Fealy N, Baldwin I, Morimatsu H, Bellomo R (2003) Continuous is not continuous: the incidence and impact of circuit “down-time” on uraemic control during continuous veno-venous haemofiltration. Intensive Care Med 29:575–578
Langenecker SA, Felfernig M, Werba A, Mueller CM, Chiari A, Zimpfer M (1994) Anticoagulation with prostacyclin and heparin during continuous venovenous hemofiltration. Crit Care Med 22:1774–1781
Oude Van mans-van Straaten HM, Wester JPJ, de Pont ACJM, Schetz MRC (2006) Anticoagulation strategies in continuous renal replacement therapy: can the choice be evidence based? Intensive Care Med 32:188–202
Broder G, Weil MH (1964) Excess lactate: an index of reversibility of shock in human patients. Science 143:1457–1459
Acknowledgments
The study was supported by the National Key Technology R&D Program (No. 2011BAI10B08), the National Clinical Key Specialty Construction Preparatory Projects, and, in part, by Guangdong Provincial Scientific Planning Project #2010B031600157. This work for Wang was also supported, in part, by the Robert Wood Johnson Foundation Nurse Faculty Scholars Program.
Conflict of interest
The authors declare no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
Xia Fu and Xinling Liang have contributed equally to this work.
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Fu, X., Liang, X., Song, L. et al. Building and validation of a prognostic model for predicting extracorporeal circuit clotting in patients with continuous renal replacement therapy. Int Urol Nephrol 46, 801–807 (2014). https://doi.org/10.1007/s11255-014-0682-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11255-014-0682-5